Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes

Immunotherapy Advances(2021)10.1093/immadv/ltab022Source: DataRank Database

A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes is a research paper published in Immunotherapy Advances (2021). On theSindex it has a DataRank of 0.778. It has been cited 22 times, with 17 citing works in its 1-hop citation network.

N/A

0.778DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access22 citations · 17 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02117765

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)Impact (FWCI 2.57)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 60%Citation Network 40%

Base Score Contribution

0.470

From this paper's citation signal

Citation Network Contribution

0.307

From 16 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 17 citers.

Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
Frontiers in Endocrinology202411 citations58 referencesContributes 0.043
Current perspectives and the future of disease-modifying therapies in type 1 diabetes
World Journal of Diabetes20246 citations54 referencesContributes 0.036
Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes
Diabetes Care202223 citations96 referencesContributes 0.033
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
Frontiers in Immunology2024120 citations147 referencesContributes 0.033
The IL-12 family of cytokines: pathogenetic role in diabetic retinopathy and therapeutic approaches to correction
Naunyn-Schmiedeberg s Archives of Pharmacology20245 citations58 referencesContributes 0.031

Authors (17)

Samuel Chow,Anne M. Pesenacker ORCID,Laura Cook ORCID,Annika C. Sun,S. Alice Long ORCID

Live enrichment

PubMed:35072168 PMC:PMC8769169 OpenAlex:https://openalex.org/W3215895013

National Institute of Allergy and Infectious Diseases

Grant: UM1AI109565

National Institute of Allergy and Infectious Diseases

Grant: U24AI118663

National Institute of Allergy and Infectious Diseases

Grant: UM01

Diabetes UK

Grant: [15]/0005232

Diabetes UK

Grant: 15/0005233

Innovative Medicines Initiative

Grant: 115797

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797

Breakthrough T1D Canada (formerly JDRF Canada)

Grant: 3-SRA-2018-629-S-B

Breakthrough T1D Canada (formerly JDRF Canada)

Grant: 3-SRA-2021-1040-M-N

Breakthrough T1D Canada (formerly JDRF Canada)

Grant: 3-SRA-2017-465-M-N

Versus Arthritis

Grant: 21738

National Institutes of Health

Grant: 5U24AI118663-02

Opening a window into immune system signaling at the fg/ml level

National Institutes of Health

Grant: 3UM1AI109565-09S1

Immune Tolerance Network

Guy’s and St Thomas’ NHS Foundation Trust

Immune Tolerance Network

National Institutes of Health

European Union’s Horizon

National Institute for Health Research (NIHR)

Leona M. and Harry B. Helmsley Charitable Trust

BC Children’s Hospital Research Institute

JDRF Canadian Clinical Trials Network

FWCI

2.57

Citation Percentile

0.9%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://academic.oup.com/immunotherapyadv/article-pdf/2/1/ltab022/44157679/ltab022.pdf

GOLDhttps://academic.oup.com/immunotherapyadv/article-pdf/2/1/ltab022/44157679/ltab022.pdf

publisherhttps://academic.oup.com/immunotherapyadv/article-pdf/2/1/ltab022/44157679/ltab022.pdf

publisherhttps://academic.oup.com/immunotherapyadv/advance-article-pdf/doi/10.1093/immadv/ltab022/41556683/ltab022.pdf

journalhttps://doi.org/10.1093/immadv/ltab022

Fields of Study

Diabetes and associated disordersPsoriasis: Treatment and PathogenesisDiabetes Management and ResearchMedicine0301 basic medicine03 medical and health sciences

Keywords

MedicineDosingInternal medicineCohortMaintenance therapyType 1 diabetesAdverse effectType 2 diabetesClinical endpointCmaxGastroenterologyImmunologyDiabetes mellitusPharmacokineticsEndocrinologyRandomized controlled trialChemotherapyClinical TrialImmunomodulatoryUstekinumab610600Research Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being